Genomic Vision

Genomic Vision ROA

The Return on Assets (ROA) of Genomic Vision (GV.PA) as of Oct 22, 2026 is -136.10 %. In the previous year, Return on Assets (ROA) was -73.81 % — a change of 84.38% (lower).

ROA

-136.10 %

YoY

84.38%

Last updated:

In 2022, Genomic Vision's return on assets (ROA) was -136.10 %, a 84.38% increase from the -73.81 % ROA in the previous year.

The Genomic Vision ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2015
-19.77 EUR
Jan 1, 2016
-65.16 EUR
Jan 1, 2017
-109.57 EUR
Jan 1, 2018
-79.24 EUR
Jan 1, 2019
-82.26 EUR
Jan 1, 2020
-70.89 EUR
Jan 1, 2021
-73.81 EUR
Jan 1, 2022
-136.10 EUR
The Genomic Vision ROA history
YEARROAYoY
-136.10 %+84.38%
-73.81 %+4.13%
-70.89 %-13.82%
-82.26 %+3.80%
-79.24 %-27.68%
-109.57 %+68.15%
-65.16 %+229.56%
-19.77 %+142.47%
-8.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

ROA Details

Understanding Genomic Vision's Return on Assets (ROA)

Genomic Vision's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Genomic Vision's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Genomic Vision's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Genomic Vision’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Genomic Vision stock

Return on Assets (ROA) of Genomic Vision is -136.10 % in 2022.

Return on Assets (ROA) of Genomic Vision changed from -73.81 % to -136.10 %, representing a 84.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Genomic Vision with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Genomic Vision

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Genomic Vision